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to result in any great changes, although in certain areas, price reductions can be 
expected. ConClusions: Some downward pressure on prices in other EU markets 
is likely as Croatia becomes a reference market for IRP, although this is likely to be 
limited in scope in the short term, with only particular products and therapeu-
tic groups affected. Over the longer term, as more markets add Croatia to their 
reference-pricing baskets, this pressure is likely to intensify.
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objeCtives: The Health (Pricing and Supply of Medical Goods) Act 2013 passed in 
June 2013 provides for generic substitution in Ireland. The aim of the study was to 
ascertain the views of the stakeholders i.e. patients, pharmacists and prescribers on 
generic substitution,prior to the Act’s introduction. Methods: Three stakeholder 
specific surveys were developed to assess knowledge of and attitudes to generic 
substitution. Convenience samples of health care professionals and patients were 
gathered until data saturation was achieved. Descriptive quantitative and qualita-
tive analysis was undertaken. Results: A total of 742 health care professionals 
and 330 patients responded. The study highlighted 4 areas where prescribers and 
pharmacists differed; (1) Prescribers ranked cost-savings as the most important 
information to impart to patients while pharmacists advocated therapeutic equiva-
lence as highest. (2) Pharmacists considered that more patients would be agreeable 
to generic substitution (52%) as compared to 41% of prescribers. (3) Prescribers 
considered that generic substitution would have a greater effect (25%) on patient 
care than pharmacists (14%). (4) 19% of prescribers supported generic substitution in 
all cases and 76% with some exceptions, compared to 16% and 84% for pharmacists 
respectively. More than 80% of patients were on between 1 and 8 medicines daily, 
and of these > 50% reported that they were on generic medicines. More than 80% 
would be happy with generic substitution, while more 75% of those interviewed 
considered generic drugs to contain the same drug, to be as effective and as safe 
as branded medicines. ConClusions: To prevent possible confusion and concern 
among patients it is important that health care professionals acquire the necessary 
tools and knowledge to manage transition into and rollout of this new system, so 
that they can work together to ensure the obvious benefits of the new system are 
maximised.
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objeCtives: Potentially inappropriate medication (PIM) in the elderly increases 
the risk of adverse drug reactions (ADR) and consequently has an impact on both 
patients’ quality of life and health care costs. In 2010, the PRISCUS list was published 
in Germany to identify PIM and to propose adequate substitution medication. The 
objective of the study was to assess both the prevalence and reimbursement of 
PIM in a German practice network applying the PRISCUS list. Moreover, costs for 
proposed surrogates were evaluated. Methods: Patients fulfilling the following 
criteria were included: (1) insured at the local health fund AOK Bavaria, (2) treated 
by physicians of the practice network, and (3) aged ≥ 65. Data was provided from 
AOK Bavaria and contained 214,177 anonymized prescriptions between Q1/2009 
and Q4/2011. Information included age, gender, date of prescription and ATC-Code. 
Since no information on dosage or package size was given, medication and its 
application duration were differentiated in acute and long-term medication by 
expert opinion. Costs were calculated by applying the concept of DDD. Results: 
On average, 16.0% of the patients received at least one PIM prescription each quarter. 
13,736 prescriptions were classified as PIM (6.4%; 68.7% to women). Out of these, 
psycholeptics such as Zopiclon (11.8%) and calcium antagonists such as Nifedipin 
(7.9%) were prescribed most frequently. Total costs of PIM-prescriptions were cal-
culated to be 446,430€ (mean 40,585€ per quarter; min. 32,869€ ; max. 50,024€ ). 
When assuming prescription of surrogates, costs varied between 267,990€ and 
935,826€ . ConClusions: PIM represents both a medical and economic burden to 
the German health care system. From an economic perspective, substitution of PIM 
may result in cost disadvantages. Thus, there is little economic incentive for health 
insurances to further promote the substitution of PIM. Future research should take 
a broader perspective and include costs of PIM-related ADR to fully evaluate the 
economic impact of PIM in the elderly.
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objeCtives: To clarify the spread with prescription of generic drugs and the shift 
from brand drug market by using nationwide administrative data. Methods: For 
the sample, out of 30 drugs seen as the parameter for generic drugs in France, 27 
have been selected after considering their availability in Japan. For those drugs 
unapproved in Japan, they were replaced by other drugs with the same effects, 
and anticancer agents as well as radio contrast agents were added. New drugs 
listed to National Health Insurance list around the same time were also included 
for comparison. Database was created by extracting the data of patients who were 
results. ConClusions: The current study extends the evaluation into Europe to 
confirm that as reimbursement decision makers continue to rigorously review new 
drug therapies, accurate, robust, peer-reviewed published and generalisable real-
world data will become particularly important for outcomes- or performance-based 
access schemes and health care budget management both in the US and Europe.
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objeCtives: To review the new drugs which were listed in the past on the Medical 
Fee Schedule of Japan, and to clarify the profile of the quasi value-based pricing 
in the Japan-style premium scheme. Methods: The information on pricing deci-
sions with premium was searched, extracted, and analyzed from the government 
documents open to public on the website of the Ministry of Health, Labour and 
Welfare in Japan. The four drug categories were focused due to data availability: 1) 
antihypertensive; 2) antidiabetic; 3) antibiotic; and 4) psychotropic, listed from April 
1998 through April 2013. The information relevant to the premium decision included 
listing dates, drug prices, premium categories, premium rates, and also clinical evi-
dence that could be associated with the premium decision. Results: Among total 
106 of new drugs, 27 have been identified with premium, whilst 79 with no premium. 
For each category, there existed 12 antihypertensive (single agent), 25 antidiabetic, 52 
antibiotic, 17 psychotropic. That is, the acquisition rate of premium for each category 
was 17%, 20%, 31% and 24%, respectively. The high proportion, 85%,of the rewarded 
premium categories was recognized in the category of “Usefulness II”, i.e., the 3rd 
ranked premium, while only one drug obtained the premium of innovativeness, the 
highest ranked premium. Regarding the benefit associated with the premium, both 
of clinical and humanistic outcomes seemed to be accepted for decision-making 
although the criteria for the decisions were not clearly indicated. ConClusions: 
The profile of the Japan-style premium scheme was clarified based on the survey 
over the new drugs listed in 1998 to 2013. The information extracted in our study 
will be useful for further investigations to improve the Japanese quasi value-based 
pricing methods.
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objeCtives: Spain has a decentralized health care systems with several levels of 
decision-making. After a drug is approved by the Spanish Agencia del Medicamento, 
regional committees (RC) conduct evaluate and assess those drugs for their use 
in ambulatory settings making recommendations to health professionals within 
its territory. The objective of this study is to analyze the structure and process of 
work of those RC. Methods: RC were contacted by phone and informed about 
this study. A web based questionnaire was ellabored including questions on: 1) 
General information of the RC; 2) Procedure of work of RC; and 3) Criteria used for 
the selection of medicines to asess and the procedures followed to. A link was sent 
by email to contact persons of the RC of the Spanish 17 Autonomous Comunities 
(AC). Results: To this date 10 RC (59%) have submitted their answers and 3 regions 
(18%) have responded indicating the absence of this type of structure or process in 
their region. These 3 regions, though, make recommendations usually conducting 
their own assessments or using assessments conducted by other regions. 7 RC 
have a normalized process of work (5 is open to the public). 8 RC have more than 8 
members. All RC evaluate medicines prescribed for outpatients purchased through 
pharmacies (5 of them exclusively), and 5 conduct also assessments of drugs used 
in hospitals. 9 RC use as comparator the standard treatment for a given indication. 
Economic evaluation is performed through budget impact (6 RC), cost-effectiveness 
(5 RC); and cost-minimization (2 RC). 6 RC make public their assessments through 
public web pages and 2 using electronic bullletins. ConClusions: Preliminary data 
indicate that the majority of Spanish regions conduct their own drug assessments, 
and most of them have established RC, whose structure and process of work show 
some variability and indicate certain degree of duplication.
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objeCtives: To assess the implications of Croatia’s accession to the European Union 
for the pricing and reimbursement landscape both in Croatia and other EU member 
states, focusing on international reference pricing. Methods: Changes to Croatia’s 
laws governing drug pricing and reimbursement were examined in detail, in rela-
tion to their likely effects on drug prices in Croatia and in other EU member states 
through international reference pricing. The IHS International Reference Pricing 
Matrix was used to determine impact of Croatian prices on other markets likely 
to include Croatia in their reference pricing basket. Interviews were conducted 
with representatives of the pharmaceutical industry in Croatia, and regulators in 
Croatia and other EU member states, to gauge their views. Results: The exist-
ence of comparatively low prices of medicines in Croatia is likely to result in some 
downward pressure on pricing in countries which include all EU countries in the 
IRP basket of countries. However, this impact is not likely to be felt immediately, 
and only for the few therapeutic areas where Croatia’s prices are among the lowest 
in Europe. Changes to Croatia’s international reference pricing basket are unlikely 
